Using continuous glucose monitoring in intensive care units
Comparison of Continuous Glucose Monitoring and Point-of-Care Measurements on the Intensive Care Unit: An Exploratory Study
This study tests if continuous glucose monitoring can provide reliable blood sugar readings for insulin-dependent patients in intensive care units compared to traditional methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Deventer Ziekenhuis Academic / other |
| Locations | 3 sites (Almelo, Overijssel and 2 other locations) |
| Trial ID | NCT06645873 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of continuous glucose monitoring (CGM) in patients admitted to intensive care units (ICUs) to assess its reliability compared to traditional point-of-care glucose measurements. It aims to identify discrepancies between CGM and point-of-care readings and whether these discrepancies vary based on patient characteristics such as age, gender, and comorbidities. The study will involve insulin-dependent ICU patients who are expected to stay in the ICU for more than two days, utilizing a prospective, multi-centre, single-arm intervention design. Participants will receive a CGM sensor to monitor their glucose levels continuously during their ICU stay.
Who should consider this trial
Good fit: Ideal candidates for this study are insulin-dependent patients aged 18 and older who are admitted to the ICU with an expected length of stay of more than two days.
Not a fit: Patients who are pregnant, undergoing therapeutic hypothermia, or have certain medical conditions such as low platelet counts or specific medication use may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved glucose monitoring in critically ill patients, potentially reducing morbidity and mortality associated with hypoglycemia and hyperglycemia.
How similar studies have performed: While studies on CGM in ICU settings are limited, the use of CGM in general diabetic management has shown significant benefits, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients admitted to the ICU * Insulin-dependent as defined in local protocol * Age: ≥ 18 y * Expected length of stay in ICU more than 2 days Exclusion Criteria: * Pregnancy * No informed consent * Therapeutic hypothermia (less than 34 degrees celsius) * Platelet count less than 50,000/μL at time of inclusion * Use of hydroxyurea * Use of acetaminophen more than 4 g/day
Where this trial is running
Almelo, Overijssel and 2 other locations
- Zorggroep Twente Almelo — Almelo, Overijssel, Netherlands (Recruiting)
- Deventer Ziekenhuis — Deventer, Overijssel, Netherlands (Recruiting)
- Medisch Spectrum Twente — Enschede, Overijssel, Netherlands (Recruiting)
Study contacts
- Study coordinator: Kim Kamphorst, Dr.
- Email: k.kamphorst@dz.nl
- Phone: +31 (0)570536273
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.